On 24 April 2019, orphan designation (EU/3/19/2152) was granted by the European Commission to TMC Pharma (EU) Limited, Ireland, for 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-pyrazol-1-YL)propanoic acid (also known as STG‑001) for the treatment of Stargardt's disease.
|Disease / condition||
Treatment of Stargardt's disease
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: